UroGen Pharma (URGN) Net Income towards Common Stockholders: 2016-2025
Historic Net Income towards Common Stockholders for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$33.3 million.
- UroGen Pharma's Net Income towards Common Stockholders fell 40.87% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 42.70%. This contributed to the annual value of -$126.9 million for FY2024, which is 24.09% down from last year.
- Latest data reveals that UroGen Pharma reported Net Income towards Common Stockholders of -$33.3 million as of Q3 2025, which was up 33.23% from -$49.9 million recorded in Q2 2025.
- In the past 5 years, UroGen Pharma's Net Income towards Common Stockholders ranged from a high of -$21.9 million in Q3 2023 and a low of -$49.9 million during Q2 2025.
- Over the past 3 years, UroGen Pharma's median Net Income towards Common Stockholders value was -$32.3 million (recorded in 2024), while the average stood at -$32.4 million.
- In the last 5 years, UroGen Pharma's Net Income towards Common Stockholders spiked by 30.62% in 2021 and then tumbled by 49.51% in 2025.
- UroGen Pharma's Net Income towards Common Stockholders (Quarterly) stood at -$28.5 million in 2021, then decreased by 1.47% to -$28.9 million in 2022, then rose by 9.88% to -$26.0 million in 2023, then slumped by 44.19% to -$37.5 million in 2024, then crashed by 40.87% to -$33.3 million in 2025.
- Its last three reported values are -$33.3 million in Q3 2025, -$49.9 million for Q2 2025, and -$43.8 million during Q1 2025.